This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Other

Hearing loss

Usher syndrome 1C (USH1C)

Mouse studies suggest using antisense oligonucleotides (ASOs) that correct splicing of mutant USH1C transcripts could help prevent Usher syndrome-associated hearing loss. In a neonatal mouse model of Usher syndrome, a single intraperitoneal injection of a splice-correcting ASO prevented development of auditory and vestibular defects, whereas injection of a control ASO did not. Next steps include optimizing the lead ASO and determining the best dosing regimen in collaboration with Isis Pharmaceuticals Inc.

SciBX 6(7); doi:10.1038/scibx.2013.171
Published online Feb. 21, 2013

Patents pending covering ASOs targeted to the mutant USH1C; licensing status undisclosed

Lentz, J.J. et al. Nat. Med.;
published online Feb. 4, 2013;
doi:10.1038/nm.3106
Contact: Michelle L. Hastings,
Rosalind Franklin University of Medicine and Science, Chicago, Ill.
e-mail:
michelle.hastings@rosalindfranklin.edu